Publications by authors named "J L Pinana"
Background: Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
Patients And Methods: We included consecutive CARV infection episodes occurring up to six months after allo-HCT registered in our database from December 2013 to June 2023 at two Spanish transplant centers.
Results: Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.
Article Synopsis
- This study aims to create predictive models for treatment outcomes in patients with relapsed/refractory B-cell lymphoma undergoing CAR-T therapy by analyzing imaging data and clinical information.
- It includes a cohort of 65 patients, utilizing imaging features from PET/CT scans to assess treatment response, overall survival, progression-free survival, and neurotoxicity risk associated with the therapy.
- The results demonstrated that combining imaging features with clinical data significantly enhances prediction accuracy for treatment-related outcomes, highlighting the importance of metabolic tumor volume (MTV) in stratifying patient prognosis.
Background: Cytomegalovirus (CMV) infection is a common complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and in patients receiving novel hematological therapies. Its impact on morbidity and mortality necessitates effective management strategies. Despite recent advances in diagnostics and treatment, unresolved questions persist regarding monitoring and treatment, prompting the need for updated recommendations.
View Article and Find Full Text PDFThe value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV PTLD).
Orphanet J Rare Dis
August 2024
Background: The aim of this study was to assess the contribution of the reflective multidisciplinary discussion in determining the value contribution of innovative drugs through the multi-criteria decision analysis (MCDA). This methodology considers all relevant criteria for healthcare decision-making in a global, transparent, and systematic manner and from the perspective of relevant stakeholders. The determination of value contribution of tabelecleucel for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV PTLD) compared to salvage therapy was used as an example.
View Article and Find Full Text PDFArticle Synopsis
- Haploidentical hematopoietic stem cell transplantation (haploSCT) is gaining traction as a viable option for patients without suitable donors, especially following the advent of post-transplantation cyclophosphamide (PTCy).
- This study analyzed 372 adult haploSCT patients who received different GVHD prophylaxis strategies, finding no significant differences in acute GVHD rates among the groups, but noted lower chronic GVHD rates in patients treated with single-agent tacrolimus.
- The results indicate that while all three prophylaxis methods (single-agent tacrolimus, CNI + MMF, sirolimus + MMF) produced similar short-term outcomes, further research is needed to explore differences in chronic GVHD